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Projects that require analytical support can evolvefrom a number
of different situations, for example new molecular entities from
drug discovery; process changes; packaging changes; site changes;
line extensions; and inlicensed projects and compounds. Laboratory
automation has been shown to provide a viable and practical
solution to assisting in analytical development. However, it is not
always the most logical answer. A truly flexible and responsive
analytical unit will make a decision on a case-by-case basis, when
faced with a new project, whether it is best to: automate some or
all aspects/testing involved; contract out to a reputable and
approved contract research organization (CRO); hire temporary
help; use available in-house resources; use a combination of the
options shown above (for example to evaluate the complexity of the
new project versus what the in-house resources are currently
working on). The paper discusses the advantages and disadvan-
tages of the various options with respect to providing analytical
support and suggests optionsfor the most effective use of resources.
The role ofautomation as one of the important tools in the arsenal
of these options is highlighted.
The drug discovery and development process
Most are familiar with the general concept of drug
discovery and development and it is not the focus of this
particular paper to discuss the various stages of the
development process in detail. However, in general, the
life cycle of a drug product follows the stages below:
Pre-Phase 0 or ’Phase 00’. This is actually not a stage
of development but rather, the final stage in the
discovery process. It involves screening of multiple
candidates against one or more screens or in vitro
assay models to determine biological activity of a
potential drug candidate. The end of this phase is
marked by the selection of a discrete candidate mol-
ecule (or very small number of molecular ana-
logues) which are presented to management and
proposed for further development.
Phase O. During Phase 0 the candidate molecule is
readied for the start of the clinical trials. Toxicology
studies are performed and the molecular forms are
characterized. Development of a suitable formula-
tion is also done during this time. If applicable,
regulatory documentation, in the form of an inves-
tigational new drug (IND) file is prepared. The
culmination of Phase 0 is marked by the dosing of
the first clinical patient.
Phase I. The beginning of the clinical programme
marks not only the end of Phase 0, but also the
beginning of Phase I. These early clinical trials
seek to demonstrate the feasibility of the drug with
respect to patient tolerance and the achievement of
desired blood levels and other related pharmacoki-
netic parameters. If the drug is not excessively toxic
or is not being used for such indications as cancer
and AIDS, the study is done with healthy volun-
teers. Successful findings in the Phase I ’Proof-of-
Concept’ trial leads to a higher level trial, that of
the Phase II dose fining or dose ranging studies.
Phase H. The goals of the Phase II trials are to show
a dose response for the drug and to explore adverse
events, so that the highest efficacious dose may be
given without causing undesirable effects. Phase II
studies (and all clinical studies after Phase I) are
done on actual patients. Such trials are supervised
by medically qualified specialists. At some point in
the latter stage of the Phase II trials, the company
developing the drug will conduct a business analysis
and make a financial commitment to continue
developing the compound, for the Phase III trials
will consume considerable resources and funds.
Phase III. The largest and most costly stage of drug
development is the multi-centre Phase III trials,
which are usually conducted globally. The goal of
Phase III is to demonstrate efficacy in a controlled
population of patients. It is the data from Phase III
that determines the final label information and ul-
timately how the product will be viewed by the
public.
Pre-NDA Phase. Even while the Phase III trials are
continuing, the preparation for the filing of the new
drug application (NDA) is already underway. The
regulatory documentation is prepared and filed
with the FDA (and other regulatory bodies if
applicable) and the site is readied for the impending
pre-approval inspection (PAI).
Pre- andpost-approval. In the months both before and
after approval of the NDA, dosage form life cycle
planning will take place, additional Phase IIIB and
Phase IV clinical studies will begin, and technical
commitments made to the regulatory authorities
both during review of the application and site
inspection will be dealt with. The development of
line extensions and novel delivery systems, and new
strengths of the active for new clinical indications
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are done to maximize return on investment and
extend the lifetime of the product.
While the above discussion centres around the ’normal’
course of drug discovery and development, starting with-
in a lead discovery centre and transferring to a develop-
ment organization, all of us in the technical or nonclinical
areas of drug development know that the pipeline from
drug discovery to development is only one of many
channels feeding the river of drug development. In
addition to the activities surrounding the bridging of a
particular molecule from concept to reality to marketed
product, the everyday work in a technical and for the rest
of this article, analytical, environment can stem from
other sources as well:
Development work from other discovery or lead
generation centres.
Strategic alliances between the company and other
scientific venues, leading to a partnership or code-
velopment of the drug.
Inlicensed molecular entities or more mature pro-
jects where the developing organization will buy the
compound outright.
New formulations and/or novel delivery systems for
existing marketed products.
Development of a generic introduction for a mature
marketed product (if the developing company has a
generic division).
Transfer of a synthetic or dosage form manufactur-
ing process to another site.
Alternate packaging presentations for existing prod-
ucts.
Problem-solving or analytical investigations sur-
rounding either an existing marketed product or
product under development.
What all of these sources have in common is that they
generate a lot of work. While some of the work may be
classified as routine, for example, stability samples for the
registration of alternate package configurations or new
formulations, there may be considerable amounts of
method development, validation, troubleshooting, pre-
paration and/or review of regulatory documentation, and
formulation and process support.
Options for handling the analytical workload
Analytical laboratory managers have become quite adept
at handling additional projects within their portfolio of
work and, at first glance to the customer, it may seem
that they must have an excess of personnel to draw upon
so that not even a single project or sample request suffers
a missed deadline. Besides prioritizing analyses and being
proactive in project planning, there are several options
available to the analytical laboratory to handle these
projects. The most prominent of these are:
Automation of entire methods and/or operations.
Examples here include the use of dissolution
robots/workstations or tablet processing worksta-
tions to perform tasks which lead to the evaluation
of large numbers of samples.
Use of ’partial automation’ as a means to move
samples through a particular portion of a method
that may be repetitious or time-consuming, or even
to improve method precision in this operation. Such
examples as pipetting, dispensing or diluting steps as
portions of larger methods fall into this category.
Employing available in-house resources to handle
the project (if those resources are available).
Reallocate resources from another project to the
new project if its priority in the organization is
higher.
Hire temporary help to handle the peaks in the
project timeline.
Use a contract research organization (CRO) as an
outsourcing partner for either a portion of the pro-
ject or the entire project.
Realizing that there are always options to getting the job
done and keeping the needs of the customer in mind, the
needs and demands of the individual projects in the work
portfolio and the degree of complexity and manpower
required to fulfil commitments need to be considered.
Examining the options available, the next set of questions
that needs to be addressed is the following:
what is the timeframe of the new project relative to
the other projects already underway in the organ-
ization?
What is the nature of the new work? Is it routine or
demanding? Will extensive training be required for
the personnel who are slated to perform the work?
Who are the partners, collaborators and customers
in the work? Who is the project driver?
What is the level of cGMP compliance required in
the project? Will the resulting data be a part of a
regulatory submission?
Is automation a realistic option? Will considerable
lead time be required to develop and validate an
automated method? Will the resulting number of
samples processed justify the up-front resources
needed to integrate automation into the project?
Is cost an issue of concern?
In trying to make decisions as to what the best course of
action would be, the analytical manager needs to con-
sider all options, both for the new project and those
already in his/her laboratory and the best use of the
resources and money available to get the job done. For
example, having every experienced, advanced level ana-
lytical scientists perform routine stability analyses is a
poor use of talent when these chemists could be applying
their skills toward such tasks as method development,
validation and problem solving. Such analytical testing
would be best performed by temporary personnel. Con-
versely, the option to place such studies at a CRO is
another option if the timeframe allows for the working up
of a quotation with the company and the execution of an
analytical transfer protocol. If the CRO has not been
used before, an audit of the facility by the compliance or
quality assurance group will have to be done as well.
Contracting is becoming quite popular in the pharma-
ceutical industry today and the number of CROs in
increasing at a rapid rate. Indeed, many research-based
pharmaceutical companies are developing contractual
arrangements in the form of strategic alliances with the
CROs to the extent that the CRO is considered a partner
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entrusting the entire registration stability program for a
series of molecules to a reputable CRO or allowing a
CRO to actually drive the development of a new mol-
ecular entity (NME) to the extent where the contractor
would perform such early development work as prefor-
mulation and excipient compatibility studies, analytical
method development, screening and development of a
Phase I dosage form, toxicology studies and toxicokinetic
analysis. As the competition between corporation be-
comes even more fierce, it is expected that the use of
CROs will increase even further in the coming years. One
of the key advantages of outsourcing is that it allows in-
house resources to be devoted to other important pro-
jects, possibly those where quick turn-around times are
needed or where the customer is in close proximity. It
also allows the resident staff to pursue scientifically
challenging projects and/or pursue process improvement
ideas and technologies, examples which may include new
analytical techniques and instrumentation. The draw-
backs to outsourcing are:
Even simple studies cost considerable money.
Methods transfer must be considered (the time and
money).
Communications may become an issue if not prop-
erly managed. This also depends on the geographi-
cal location of the CRO relative to the company.
The involvement of a quality assurance organiz-
ation to monitor the cGMP compliance level of
the CRO is required.
If the project is developmental, such that it will lead
to clinical studies and eventually to a regulatory
filing, the CRO will become an additional site for
a Pre-Approval Inspection (PAl). It is the absolute
responsibility of the hiring company to make sure
the CRO is compliant and prepared for the inspec-
tion when it occurs.
Outsourcing still requires in-house resources in the
form of personnel to manage the data coming from
the CRO and handle the billing and invoicing that
accompanies the data.
If the project contracted out is one which will result
in a regulatory filing, not performing the work in-
house results in a loss of expertise in that the experi-
ence with the NME, formulation and project is not
fostered in-house, but rather at the CRO. This may
not be devastating, although turnover at most
CROs has been an issue of concern with hiring com-
panies.
As an alternative to the use of CROs, temporary employ-
ees can be hired to handle additional work. The ad-
vantages of using such workers is that they consume very
little overhead expenses (i.e. benefits), their management
is done through contract, they offer a pool of proba-
tionary workers which can be drawn upon if and when
positions become available. One disadvantage (especially
at this point in time) is that the upswing in the
pharmaceutical industry job market is making good
temporary analysts hard to keep unless they are made
permanent. Another drawback which ties into the pre-
vious point is that the ownership of the project is not
fostered with the permanent scientific staff of the com-
pany and if the temporary employee resigns, then the
knowledge and project-related experience will depart
with that person. Some temporary workers make looking
for a permanent position a priority, which can be
problematic, especially in larger organization.
Last but not least, is the use of robotics and automation
in an environment of limited resources. Indeed, there
have been a plethora of presentations at the ISLAR
meetings over the past several years lauding the virtues
of automation for a variety of situations and tasks.
Caution should be exercised that the ’correct’ matches
for the abilities of robotics and the demands of the project
be established. One must also remember the validation
criteria for a robotic system that will be used in a cGMP
application. Training of the personnel who will use the
robot for analysis must also be considered. The analysis of
the resulting data must be a priority of using the robot in
a timesaving mode will be for naught. It should be
pointed out that utilizing laboratory robotics may cause
slight changes in the local areas in which they are being
utilized. For example, stability setup for a particular
project, most often consisting of multiple lots and/or
package configurations, are set up in such a fashion so
as to be staggered with respect to their analysis dates
so the analytical laboratory is not overwhelmed with
samples followed by a complete lapse in samples. When
using a robot to perform the same analyses, it is more
efficient to cause all the samples to come off station
simultaneously so the robot is utilized in its night and
day analytical mode. This also saves the operators the
chore of running standards for the robot multiple times.
Conclusions
Laboratory automation offers but one solution to
the ever expanding analytical work portfolio.
Robotics are not the answer to the needs of every
project.
One needs to consider both the type and volume of
work, as well as the priority, when choosing a sol-
ution to a problem.
Both outsourcing and temporary employees have
advantages and disadvantages when used to offset
increased workload.
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